Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 5/20 | 0.44 |
| ▸ | MEN1 | O00255 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | RECQL | P46063 | 2/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | PLEC | Q15149 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2473827 | 0.81 | F2 (0.41) | TSHRPOLBMEN1KMT2AMAPT | |
| SCHEMBL2471712 | 0.80 | RAB9A (0.38) | TSHRPOLBMEN1KMT2AL3MBTL1 | |
| SCHEMBL2473208 | 0.78 | GAA (0.43) | POLBMEN1KMT2AL3MBTL1MAPT | |
| SCHEMBL2475555 | 0.77 | F2 (0.44) | TSHRPOLBMEN1KMT2AMAPT | |
| SCHEMBL2477437 | 0.76 | TSHR (0.38) | TSHRPOLBMEN1KMT2AL3MBTL1 | |
| SCHEMBL2477436 | 0.76 | TSHR (0.38) | TSHRPOLBMEN1KMT2AL3MBTL1 | |
| SCHEMBL2477288 | 0.75 | F2 (0.44) | TSHRPOLBMEN1KMT2AMAPT | |
| SCHEMBL3833661 | 0.75 | NPC1 (0.47) | POLBMEN1KMT2AL3MBTL1MAPT | |
| SCHEMBL3050480 | 0.72 | TAAR1 (0.38) | MEN1KMT2AMAPT | |
| SCHEMBL85578 | 0.71 | SCN2A (0.54) | POLBMEN1KMT2AL3MBTL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2563762-B1 | METHOD FOR PRODUCING SUBSTITUTED PYRIDIN-2-ONE | BAYER IP GMBH (DE) | 2015-07-22 | — | — | EP | disclosed |
| CN-102906071-B | Method for producing substituted pyridin-2-one | BAYER IP GMBH | 2015-03-18 | — | — | CN | disclosed |
| CN-102906071-B | Method for producing substituted pyridin-2-one | BAYER IP GMBH | 2015-03-18 | — | — | CN | disclosed |
| US-8802860-B2 | Method for producing substituted pyridin-2-one | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-08-12 | — | — | US | disclosed |
| US-8802860-B2 | Method for producing substituted pyridin-2-one | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-08-12 | — | — | US | disclosed |
| US-20130116443-A1 | METHOD FOR PRODUCING SUBSTITUTED PYRIDIN-2-ONE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-05-09 | — | — | US | disclosed |
| US-20130116443-A1 | METHOD FOR PRODUCING SUBSTITUTED PYRIDIN-2-ONE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-05-09 | — | — | US | disclosed |
| EP-2563762-A1 | METHOD FOR PRODUCING SUBSTITUTED PYRIDIN-2-ONE | Bayer Intellectual Property GmbH (DE) | 2013-03-06 | — | — | EP | disclosed |
| EP-2563762-A1 | METHOD FOR PRODUCING SUBSTITUTED PYRIDIN-2-ONE | Bayer Intellectual Property GmbH (DE) | 2013-03-06 | — | — | EP | disclosed |
| CN-102906071-A | Method for producing substituted pyridin-2-one | Bayer Pharma AG | 2013-01-30 | — | — | CN | disclosed |
| WO-2011134963-A1 | METHOD FOR PRODUCING SUBSTITUTED PYRIDIN-2-ONE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-11-03 | — | — | WO | disclosed |
| WO-2011134963-A1 | METHOD FOR PRODUCING SUBSTITUTED PYRIDIN-2-ONE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116443-A1 | METHOD FOR PRODUCING SUBSTITUTED PYRIDIN-2-ONE | PNPO, CYP4B1, DPYD | TSHR 2170/4885POLB 1848/4885MEN1 811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.